Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial

Autor: Zhongjun Xia, Yun Leng, Baijun Fang, Yang Liang, Wei Li, Chengcheng Fu, Linhua Yang, Xiaoyan Ke, Hua Jiang, Jianyu Weng, Li Liu, Yaozhong Zhao, Xuejun Zhang, Zhongxia Huang, Aichun Liu, Qingzhi Shi, Yuhuan Gao, Xiequn Chen, Ling Pan, Zhen Cai, Zhao Wang, Yafei Wang, Yaqun Fan, Ming Hou, Yigai Ma, Jianda Hu, Jing Liu, Jianfeng Zhou, Xiaohong Zhang, Haitao Meng, Xuzhang Lu, Fei Li, Hanyun Ren, Bintao Huang, Zonghong Shao, Hebing Zhou, Yu Hu, Shifang Yang, Xiangjun Zheng, Peng Wei, Hongyan Pang, Wei Yu, Yuzhang Liu, Sujun Gao, Lingzhi Yan, Yanping Ma, Hongmei Jing, Juan Du, Wei Ling, Jingyi Zhang, Weiwei Sui, Fuxu Wang, Xin Li, Wenming Chen

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)

Abstract Background Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in p

Externí odkaz: https://doaj.org/article/b54d9a34e0c7454a9a0589390ee8abee

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.

Autor: Croft M; Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, CA, USA. mick@lji.org., Salek-Ardakani S; Inhibrx, La Jolla, CA, USA. shahram@inhibrx.com., Ware CF; Laboratory of Molecular Immunology, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA. cware@sbpdiscovery.org.

Publikováno v: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2024 Dec; Vol. 23 (12), pp. 939-961. Date of Electronic Publication: 2024 Oct 24.